logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Keratoconjunctivitis Sicca

    Medications for Keratoconjunctivitis Sicca

    FiltersReset Filters
    5 results

    • cequa

      (cyclosporine)
      Sun Pharmaceutical Industries, Inc.
      Usage: CEQUA ophthalmic solution is indicated for increasing tear production in patients with keratoconjunctivitis sicca (dry eye) as a calcineurin inhibitor immunosuppressant.

    • cyclosporine

      (cyclosporine)
      Devatis Inc.
      Usage: Cyclosporine ophthalmic emulsion is indicated for increasing tear production in patients with keratoconjunctivitis sicca, particularly when tear production is suppressed due to ocular inflammation. It is not effective in patients already using topical anti-inflammatory drugs or punctal plugs.

    • lacrisert

      (hydroxypropyl cellulose)
      Bausch & Lomb Incorporated
      Usage: LACRISERT is indicated for treating moderate to severe dry eye syndromes, including keratoconjunctivitis sicca, particularly in patients who do not respond adequately to artificial tears. It is also used for exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

    • restasis

      (cyclosporine)
      Allergan, Inc.
      Usage: RESTASIS® ophthalmic emulsion is indicated for increasing tear production in patients with keratoconjunctivitis sicca, whose tear production is likely suppressed due to ocular inflammation. It is not effective in patients currently using topical anti-inflammatory drugs or punctal plugs.

    • restasis multidose

      (cyclosporine)
      Allergan, Inc.
      Usage: RESTASIS MULTIDOSE ophthalmic emulsion is indicated to increase tear production in patients with keratoconjunctivitis sicca, particularly when tear production is presumed suppressed due to ocular inflammation. It is not effective in patients currently using topical anti-inflammatory drugs or punctal plugs.